SCHEMBL33352

SCHEMBL33352

C=C(C)C(=O)c1cc(N)ccc1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.52
KDM4E B2RXH2 6/20 0.52
TDP1 Q9NUW8 6/20 0.52
KMT2A Q03164 6/20 0.52
MEN1 O00255 5/20 0.52
MAPT P10636 4/20 0.52
THRB P10828 2/20 0.52
RECQL P46063 2/20 0.52
CYP3A4 P08684 2/20 0.52
GAA P10253 2/20 0.52
POLB P06746 2/20 0.52
CYP2C9 P11712 2/20 0.52
CYP2C19 P33261 2/20 0.52
HSD17B10 Q99714 2/20 0.52
MCL1 Q07820 2/20 0.52
ALOX15 P16050 2/20 0.52
USP2 O75604 1/20 0.52
PKM P14618 1/20 0.52
APEX1 P27695 1/20 0.52
BLM P54132 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8047571 0.81 ALDH1A1 (0.59) ALDH1A1KDM4ETDP1KMT2AMEN1
SCHEMBL231377 0.80 ALDH1A1 (0.68) ALDH1A1KDM4ETDP1KMT2AMEN1
SCHEMBL29364937 0.80 ALDH1A1 (0.68) ALDH1A1KDM4ETDP1KMT2AMEN1
SCHEMBL2810654 0.78 ALDH1A1 (0.65) ALDH1A1KDM4ETDP1KMT2AMEN1
SCHEMBL28520448 0.78 ALDH1A1 (0.65) ALDH1A1KDM4ETDP1KMT2AMEN1
SCHEMBL2809853 0.78 ALDH1A1 (0.65) ALDH1A1KDM4ETDP1KMT2AMEN1
SCHEMBL8611991 0.78 GAA (0.50) ALDH1A1KDM4EKMT2AMEN1MAPT
Aminosalicylic Acid SCHEMBL15872182 0.77 ALDH1A1 (0.76) ALDH1A1KDM4ETDP1KMT2AMEN1
SCHEMBL8612851 0.77 ALOX5 (0.39) ALDH1A1KDM4ETDP1KMT2AMEN1
Nitrogen SCHEMBL28683357 0.77 ALDH1A1 (0.63) ALDH1A1KDM4ETDP1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1973587-A2 METHODS AND SYSTEMS FOR PREPARING ANTIMICROBIAL FILMS AND COATINGS Allaccem, Inc. (US) 2008-10-01 EP claimed
WO-2007070801-A2 METHODS AND SYSTEMS FOR PREPARING ANTIMICROBIAL FILMS AND COATINGS ALLACCEM, INC. (US) 2007-06-21 WO claimed
US-7226960-B2 Self-etching primer adhesive and method of use therefor PENTRON CLINICAL TECHNOLOGIES, LLC (US) 2007-06-05 US claimed
US-20030207960-A1 Self-etching primer adhesive and method of use therefor PENTRON CLINICAL TECHNOLOGIES, LLC 2003-11-06 US claimed
US-6326417-B1 CONTAINING SALICYLIC ACID COMPOUND AS MICROBIOCIDES JENERIC/PENTRON INCORPORATED 2001-12-04 US claimed
US-20250382506-A1 SHELF STABLE ADHESIVE COMPOSITIONS UNIV KANSAS (US) 2025-12-18 US disclosed
US-20250340760-A1 ADHESIVE COMPOSITIONS CONTAINING MAGNETIC PARTICLES UNIV KANSAS (US) 2025-11-06 US disclosed
US-12351745-B2 Single-component adhesive compositions OHIO STATE INNOVATION FOUNDATION (US) 2025-07-08 US disclosed
EP-4547770-A1 ADHESIVE COMPOSITIONS CONTAINING MAGNETIC PARTICLES University of Kansas (US) 2025-05-07 EP disclosed
EP-4547771-A1 SHELF STABLE ADHESIVE COMPOSITIONS University of Kansas (US) 2025-05-07 EP disclosed
US-20240082457-A1 HARD TISSUE REPAIR ADHESIVE COMPOSITION AND HARD TISSUE REPAIR KIT THEREOF Jiaxing Jingyin Biotechnology Co., Ltd. (CN) 2024-03-14 US disclosed
US-20240016973-A1 ADHESIVE COMPOSITION FOR HARD TISSUE REPAIR Jiaxing Jingyin Biotechnology Co., Ltd. (CN) 2024-01-18 US disclosed
EP-1782833-A2 pH-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy ZENTIVA, A.S. (CZ) 2007-05-09 EP disclosed
US-20060057099-A1 Ph-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy ZENTIVA, K.S. (CZ) 2006-03-16 US disclosed
EP-1463529-A2 PH-SENSITIVE POLYMERIC CONJUGATES OF AN ANTHRACYCLINE CANCEROSTATIC DRUG FOR TARGETED THERAPY ZENTIVA, A.S. (CZ) 2004-10-06 EP disclosed
US-20030207960-A1 Self-etching primer adhesive and method of use therefor PENTRON CLINICAL TECHNOLOGIES, LLC 2003-11-06 US disclosed
WO-2003053473-A2 PH-SENSITIVE POLYMERIC CONJUGATES OF AN ANTHRACYCLINE DRUG ZENTIVA, A.S. (CZ) 2003-07-03 WO disclosed
US-20020045678-A1 Dental restorative compositions and method of use thereof JENERIC/PENTRON INCORPORATED 2002-04-18 US disclosed
WO-2002015848-A2 DENTAL RESTORATIVE COMPOSITIONS AND METHOD OF USE THEREOF JENERIC/PENTRON INCORPORATED (US) 2002-02-28 WO disclosed
US-6326417-B1 CONTAINING SALICYLIC ACID COMPOUND AS MICROBIOCIDES JENERIC/PENTRON INCORPORATED 2001-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250340760-A1 ADHESIVE COMPOSITIONS CONTAINING MAGNETIC PARTICLES FN1, EPCAM, VCL ALDH1A1 1615/4885KDM4E 2337/4885TDP1 3907/4885
US-20060057099-A1 Ph-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy SLC7A1, DNPEP, ANPEP ALDH1A1 2755/4885KDM4E 3427/4885TDP1 1920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.